Skip to main content

Table 3 Association of clinico-pathological characteristics with POLE protein expression in Endometrial cancer

From: Germline POLE and POLD1 proofreading domain mutations in endometrial carcinoma from Middle Eastern region

 

Total

Low

High

p value

No.

%

No.

%

No.

%

No. of patients

414

 

170

41.1

244

58.9

 

Age (years)

 ≤ 50

76

18.4

33

43.4

43

56.6

0.6444

 > 50

338

81.6

137

40.5

201

59.5

 

Histologic subtype

 Type I

356

88.6

148

41.6

208

58.4

0.3741

 Type II

46

11.4

16

34.8

30

65.2

 

Lymphovascular invasion

 Present

88

27.4

39

44.3

49

55.7

0.2861

 Absent

233

72.6

88

37.8

145

62.2

 

Grade

 Grade 1

140

34.9

46

32.9

94

67.1

0.0308

 Grade 2

138

34.4

66

47.8

72

52.2

 

 Grade 3

123

30.7

54

43.9

69

56.1

 

pT

 T1

289

70.0

113

39.1

176

60.9

0.5879

 T2

53

12.8

26

49.1

27

50.9

 

 T3

53

12.8

22

41.5

31

58.5

 

 T4

18

4.4

8

44.4

10

55.6

 

pN

 N0

384

92.7

155

40.4

229

59.6

0.3051

 N1–N2

30

7.3

15

50.0

15

50.0

 

pM

 M0

392

94.9

163

41.6

229

58.4

0.2278

 M1

21

5.1

6

28.6

15

71.4

 

Stage

 I

267

64.7

104

39.0

163

61.0

0.5759

 II

46

11.1

22

47.8

24

52.2

 

 III

66

16.0

30

45.5

36

54.5

 

 IV

34

8.2

13

38.2

21

61.8

 

Microsatellite status

 MSI

52

12.6

25

48.1

27

51.9

0.2743

 MSS

362

87.4

145

40.1

217

59.9

 

POLE mutation

 Present

2

0.5

0

0.0

2

100.0

0.1452

 Absent

412

99.5

170

41.3

242

58.7

 

5 year overall survival

   

89.7

 

85.8

0.4691